ArticleCancer genomics & proteomics
Lower
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ReducedCancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimClear cell renal cell carcinoma (ccRCC), the most prevalent form of kidney cancer, often presents or recurs as an advanced, aggressive, and lethal disease. Thus, biomarkers are needed to identify patients at risk of developing advanced-stage or treatment-resistant ccRCC. SYNJ2BP, a cytoplasmic scaffolding protein, regulates ACVR2 activity, a key mediator of signaling pathways involved in tumor progression and metastasis. This study aimed to ascertain if MATERIALS AND
methodsBioinformatic analysis and immunohistochemistry were applied to investigate the relationship between SYNJ2BP expression, the immune landscape, and survival outcomes in ccRCC. We utilized data from publicly available databases, including The Cancer Genome Atlas, Gene Set Cancer Analysis (TCGA), and various other databases.
resultsIn-silico analyses revealed that
conclusionSYNJ2BP is a novel prognostic biomarker for ccRCC and the down-regulation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.